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ABSTRACT
Background: The aim of this study was the development and pharmacokinetic/pharmacodynamic evaluation of the in vivo release of 
subcutaneous implants of carvedilol capable of providing stable tissue levels in experimental models of hypertension.
Methods: The subcutaneous implants were prepared with poly (epsilon-caprolactone) (PCL) and different proportions of the Solu-
Plus (SP) hydrophilic polymer (300:0; 250:50; 150:150 and 50:250 mg) loaded with 100 mg carvedilol. The plasma profile and the 
effect on systolic blood pressure (SBP) after subcutaneous implantation of each formulation was evaluated in male spontaneously 
hypertensive rats (SHR).
Results: The PCL:SP 50:250 and 150:150 formulations provided levels ranging from 100 to 200 ng/mL and the PCL:SP 250:50 and 
300:0 formulations provided lower concentrations of carvedilol ranging from 0 to 100 ng/mL during the treatment period. Spontane-
ously hypertensive animals treated with the PCL:SP 50:250 y 150:150 implants presented a significant decrease in SBP (PCL:SP 
50:250: ΔPAS: –36.6 ± 2.0 mm Hg; PCL:SP150:150: -35.7 ± 2.2 mmHg; p < 0.05 vs. baseline values)
Conclusions: The incorporation of the SoluPlus hydrophilic polymer in PC:SP 150:150 and 50:250 implants increases the release 
of carvedilol, since it provides plasma concentrations ranging from 100 to 200 ng/ml, resulting in a sustained reduction of indirect 
SBP in SHR.
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RESUMEN
Objetivo: El objetivo del presente estudio fue el desarrollo y la evaluación farmacocinética y farmacodinámica de la liberación in 
vivo de implantes subcutáneos de carvedilol capaces de aportar niveles tisulares estables en modelos experimentales de hipertensión 
arterial.
Material y métodos: Se prepararon implantes subcutáneos de poli (epsilon-caprolactona) (PCL) con diferentes proporciones del 
polímero hidrofílico SoluPlus (300:0; 250:50; 150:150 y 50:250 mg) cargados con 100 mg de carvedilol. Se evaluó el perfil plasmático 
y el efecto sobre la presión arterial sistólica (PAS) luego del implante de cada formulación en el tejido subcutáneo de ratas espon-
táneamente hipertensas (REH) macho.
Resultados: Las formulaciones PCL:SP 50:250 y 150:150 aportaron niveles en el rango de 100-200 ng/mL. Las formulaciones PCL:SP 
250:50 y 300:0 aportaron concentraciones inferiores de carvedilol comprendidas en el rango de los 0-100 ng/mL durante el transcurso 
del tratamiento. Los animales espontáneamente hipertensos tratados con PCL:SP 50:250 y 150:150 experimentaron un descenso 
significativo de la presión arterial sistólica (PCL:SP 50:250: ΔPAS: –36,6 ± 2,0 mmHg; PCL:SP150:150:-35,7 ± 2,2 mmHg; p < 0,05 
vs. basal).
Conclusiones: La incorporación del polímero hidrofílico SoluPlus en los implantes PCL:SP 150:150 y 50:250 favorece un incremento 
de la liberación de carvedilol, ya que  aporta concentraciones plasmáticas del ß-bloqueante que aseguran una reducción sostenida de 
la PAS indirecta en animales espontáneamente hipertensos.
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INTRODUCTION
Hypertension is still the leading cause of mortality 
worldwide and represents the main risk factor for car-
diovascular disease. (1) Prevention of cardiovascular 
events associated with hypertension requires not only 
effective blood pressure reduction, but also the 24-
hour attenuation of blood pressure variability. (2-5) A 
key aspect of antihypertensive therapy is to achieve 
and maintain persistent blood pressure control during 
24 hours to ensure attenuation of the blood pressure 
morning surge. (6)
Carvedilol is a nonselective ß-blocker with vasodi-
lating activity secondary to α1-adrenergic blockade 
and additional pleiotropic actions, including antioxi-
dant, anti-inflammatory and antiapoptotic effects. (7) 
Compared to conventional ß-blockers, carvedilol has 
demonstrated better hemodynamic and metabolic 
profile. (8) However, one limitation of carvedilol for 
the treatment of hypertension is its low oral bioavail-
ability and rapid systemic clearance, which adversely 
affect sustained blood pressure reduction and blood 
pressure variability. In this setting, carvedilol encoun-
ters first-pass metabolism after oral administration 
resulting in low bioavailability (about 25%) and short 
elimination half-life of only 2 h. (9)  
In view of these facts, several research groups have 
developed different formulations of carvedilol to in-
crease bioavailability and prolong the duration of the 
ß-blocker in the organism. In this context, carvedilol 
nanoparticles have been developed using chitosan or 
Eudragit® RS100 polymer. (10, 11) These formula-
tions have been shown to improve the pharmacoki-
netic characteristics, although the impact on the con-
trol of hemodynamic variables and on prevention of 
target organ damage have not been evaluated. (10, 11) 
In our laboratory, we have developed subcutaneous 
implants of carvedilol with the goal of establishing the 
usefulness of these pharmaco-technical developments 
in optimizing the prevention of target organ damage 
associated with experimental hypertension.
The aim of this study was the development and 
pharmacokinetic/pharmacodynamic evaluation of the 
in vivo release of different subcutaneous implants of 
carvedilol in spontaneously hypertensive rats (SHR).
METHODS
Subcutaneous implants of carvedilol
Subcutaneous implants were prepared with poly (epsilon-
caprolactone) (PCL) and different proportions of SoluPlus 
(SP) hydrophilic polymer (300:0; 250:50; 150:150 and 50:250 
mg) loaded with 100 mg carvedilol using the melt-molding-
compression method. To prepare the PCL and SP implants 
loaded with carvedilol 100 mg, the polymers and the drug 
powder were mixed in different weight ratios, placed in an 
11-mm diameter stainless steel mold and firmly compressed 
with a punch, then heated in a preheated oven (70 ºC, 1 h) 
and compressed (0.713 kg/cm2) during the entire heating 
treatment. Next, the molds were cooled (4 ºC, 30 min) and, 
finally, the samples were removed to obtain disk-shaped im-
plants (11 mm diameter). 
Animals
Spontaneously hypertensive male rats (22-220 g) were 
trained during 2 weeks for systolic blood pressure (SBP) 
measurement using the previously described indirect tail-
cuff method. (12) After estimating baseline SBP for 3 days, 
the rats were anesthetized with intraperitoneal ketamine 
(75 mg/kg) and xylazine (10 mg/kg) and one of the follow-
ing subcutaneous implants loaded with carvedilol was placed 
under the skin at the back of the neck: PCL:SP 300:0 (n 
= 5), PCL:SP 250:50 (n = 5), PCL:SP 150:150 (n = 5) y 
PCL:SP 50:250 (n = 5). Every day during the next 2 weeks 
after implantation, indirect SBP was measured and 100 µL 
of venous blood was drawn from the lateral vein of the tail to 
determine carvedilol levels.
Systolic blood pressure was measured by the indirect 
tail-cuff method using a sphygmomanometer coupled to a 
Grass 7C polygraph (Grass Instrument Co., Quincy, MA 
USA). The animals were first conditioned in a thermostated 
room for 60 min and then transferred to a special acrylic 
tube heated at 37 ± 1 ºC to measure SBP. Indirect SBP was 
calculated as the average of six separate measurements dur-
ing the same day.  
Plasma levels of carvedilol were measured by liquid chro-
matography with fluorometric detection using an analytical 
method validated in the laboratory. (13) 
Pharmacokinetic analysis
The pharmacokinetic time course of carvedilol plasma lev-
els was analyzed applying a noncompartmental model with 
first-order elimination. The pharmacokinetic parameters: 
area under the curve (AUC), maximum plasma concen-
tration (Cmax), time to maximum plasma concentration 
(tmax), and elimination half-life (t1/2) were estimated using 
TOPFIT 2.0 software (Dr Karl Thomae Gmbh, Schering AG, 
Germany). 
Statistical analysis
The Kolmogorov-Smirnov test was used to evaluate nor-
mal distribution of data and study variables. Results were 
expressed as mean ± standard error of the mean (SEM). 
Statistical comparison between treatment groups was per-
formed using one-way ANOVA followed by Tukey’s method 
as post-hoc test using GraphPad Prism version 6.0 (Graph-
Pad Software, San Diego, California, USA). A p value <0.05 
was considered statistically significant. 
Ethical considerations
The experiments with animals were carried out in accord-
AUC Area under the curve
SBP Systolic blood pressure
PCL Poly-epsilon-caprolactone
SHR Spontaneously hypertensive rats
SP SoluPlus
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ance with the “Guide for the Care and Use of Laboratory 
Animals” (NIH publication 85-3, 1985 Revision) and were 
approved by the Ethics Committee of the School of Phar-
macy and Biochemistry of the University of Buenos Aires 
(EXP-UBA No. 0037832/2019).
RESULTS
The different disk-shaped carvedilol implants had a 
diameter of 11 mm (Figure 1). The insertion of carve-
dilol implants under the skin at the back of the neck 
was successful in all cases with no signs of pain or 
behavioral changes in the animals during the assess-
ment period.
The different types of carvedilol implants devel-
oped provided relatively stable levels of the ß-blocker 
for two weeks (Figure 2). The PCL:SP 50:250 and 
150:150 formulations provided levels ranging from 
100 to 200 ng/mL for most of the 2-week follow-up 
period (Figure 2). On day 12 after the implants were 
placed, carvedilol plasma concentrations were 174 ± 
39 ng/mL and 113 ± 20 ng/mL with PCL:SP 50:250 
and 150:150 implants, respectively (Figure 2). The 
PCL:SP 250:50 and 300:0 formulations provided low-
er concentrations of carvedilol, ranging from 0 to 100 
ng/mL during the treatment period (Figure 2). 
Table 1 shows the main pharmacokinetic param-
eters of carvedilol plasma profiles in the different ex-
perimental groups. The PCL:SP 50:250 formulation 
was associated with higher carvedilol Cmax and AUC 
compared with the other implants studied (Table 1). 
Carvedilol bioavailability after subcutaneous implant 
with the PCL:SP 150:150 formulation was higher 
than that measured in the PCL:SP 250:50 and 300:0 
groups (Table 1).
Follow-up of indirect SBP measurement after sub-
cutaneous insertion of the carvedilol implant showed 
a significant decrease of SBP from day 3 to day 15 in 
SHR treated with PCL:SP 50:250 and PCL:SP 150:150 
formulations (Figure 3). In contrast, groups treated 
with PCL:SP 250:50 and PCL:SP 300:0 implants did 
not experience a significant decrease in indirect SBP 
compared with baseline values (Figure 3).
Fig. 1. Photograph of a subcu-
taneous implant of carvedilol 
developed in the laboratory.
Fig. 2. Carvedilol plasma lev-
els after placement of differ-
ent types of implants in SHR. 
Each data point is represent-
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DISCUSSION
In the present study, the development of subcutane-
ous carvedilol implants using different proportions 
of PCL and SP polymers has proved to be an effec-
tive pharmaco-technical strategy for maintaining 
sustained levels of carvedilol for more than 2 weeks. 
Those implants with a higher proportion of SP pro-
vided higher stable plasma concentrations compared 
to PCL:SP 250:50 and PCL:SP 300:0 formulations, al-
lowing a sustained reduction of indirect SBP in SHR.
The effective prevention of target organ damage 
associated with hypertension requires effective con-
trol of both central blood pressure and blood pressure 
variability without generating adverse metabolic ef-
fects. (8) Overactivation of the sympathetic nervous 
system plays a key role in the development and main-
tenance of hypertension, so modulating sympathetic 
overactivity represents an important goal of treat-
ment. (14) Despite the recognized importance of the 
sympathetic nervous system in the development of hy-
pertension, ß-blockers are no longer recommended as 
first-line treatment due to clinical trial evidence sug-
gesting reduced cardioprotection as a result of their 
limited effects on central blood pressure and blood 
pressure variability, and the development of adverse 
metabolic effects. (15-17) However, these limitations 
are typical of conventional ß-blockers, especially aten-
olol, and do not seem to be extrapolated to vasodilator 
ß-blockers with pleiotropic action, such as carvedilol. 
(8) Clinical trial results and evaluations conducted 
in experimental models of hypertension have estab-
lished that chronic treatment with carvedilol is more 
effective than with atenolol in reducing central blood 
pressure and blood pressure variability, hemodynamic 
properties that suggest greater protection from target 
organ damage associated with hypertension. (8)
Despite the improved hemodynamic profile of 
carvedilol, a limitation of this vasodilator ß-blocker is 
its rapid systemic elimination, affecting its ability to 
maintain a sustained reduction in blood pressure for 
24 hours. (9) A clinical measure that quantifies the 
24-hour therapeutic coverage provided by an antihy-
pertensive agent is the trough-to-peak ratio, which 
represents the relationship between maximal BP de-
crease and its reduction before the administration of 
the next dose. (6) Thus, a higher trough-to-peak index 
indicates a longer duration of action affording an op-
timal therapeutic coverage during the early morning 
hours with lower risk of adverse events. (6)
While a trough-to-peak ratio around 0.5 to 0.75 is 
acceptable, a ratio closer to 1 ensures that the antihy-
pertensive effect is maintained throughout the dosing 
interval. (6) Comparative clinical trials have demon-
strated that antihypertensive agents with a trough-
to-peak ratio of 0.9 ensure greater attenuation of the 
early morning blood pressure surge than those with 
a trough-to-peak ratio of around 0.5. (18) In the case 
of carvedilol, the trough-to-peak ratio of commercially 
available immediate-release and extended-release for-
mulations is less than 0.8. (6) 
In this context, we have considered the need to de-
velop extended-release formulations of carvedilol us-
Fig. 3. Changes in indirect 
SBP in SHR after placement 
of the different subcutane-
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Table 1. Pharmacokinetic pa-






























AUC: Area under the curve. * p < 0.05 vs. PCL:SP 150:150; # p < 0.05 vs. PCL:SP 250:50; & p < 0.05 vs. PCL:SP 
300:0.
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